MARKET

NRIX

NRIX

Nurix Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.36
-0.28
-0.74%
After Hours: 37.36 0 0.00% 16:00 11/23 EST
OPEN
38.41
PREV CLOSE
37.64
HIGH
41.65
LOW
36.42
VOLUME
170.45K
TURNOVER
--
52 WEEK HIGH
41.65
52 WEEK LOW
15.21
MARKET CAP
1.38B
P/E (TTM)
-16.9741
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Nurix Therapeutics to Present Preclinical Data At Upcoming 5th Medicinal Chemistry & Protein Degradation Summit Nov. 16 And 62nd American Society of Hematology Annual Meeting And Exposition Dec. 7
SAN FRANCISCO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it will present
Benzinga · 11/04 21:14
Nurix Therapeutics EPS misses by $0.19, misses on revenue
Nurix Therapeutics (NRIX): Q3 GAAP EPS of -$0.59 misses by $0.19.Revenue of $4.09M (-61.3% Y/Y) misses by $2.25M.Press Release
Seekingalpha · 10/14 20:09
Nurix Therapeutics Q3 EPS $(0.59) Misses $(0.41) Estimate, Sales $4.08M Miss $6.34M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.41) by 43.9 percent. This is a 10.61 percent increase over losses of $(0.66) per share
Benzinga · 10/14 20:07
Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit
SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually. Additional details on the presentation
GlobeNewswire · 10/06 13:00
Nurix Therapeutics started at buy with $34 stock price target at Stifel Nicolaus
marketwatch.com · 08/18 11:43
JP Morgan Initiates Coverage On Nurix Therapeutics with Overweight Rating, Announces Price Target of $35
JP Morgan analyst Eric Joseph initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Overweight rating and announces Price Target of $35.
Benzinga · 08/18 09:36
IPO Update: Kymera Therapeutics Readies $125 Million IPO
Kymera Therapeutics has filed proposed terms for its U.S. IPO.The firm is developing treatments for various skin and immune system conditions.KYMR is still at a preclinical stage, so the IPO is ultra-high-risk and likely more suited to institutional investors with long time horizons.
Seekingalpha · 08/17 23:02
U.S. IPO Weekly Recap: Software And SPACs Shine In A 7-IPO Week
Seeking Alpha · 07/25 20:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRIX. Analyze the recent business situations of Nurix Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NRIX stock price target is 36.60 with a high estimate of 40.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 64
Institutional Holdings: 31.84M
% Owned: 85.98%
Shares Outstanding: 37.04M
TypeInstitutionsShares
Increased
0
0
New
64
31.84M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Director
Tim Kutzkey
Chief Scientific Officer
Mark Gallop
Vice President - Finance/Primary Contact
Hans Van Houte
Other
Pierre Beaurang
Director/Chief Executive Officer
Arthur Sands
Director
Perry Karsen
Director
David Lacey
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NRIX
Nurix Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. It uses its DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607 and DeTIL-0255. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Its E3 ligase inhibitor portfolio is comprised of a series of small molecule inhibitors of CBL-B, which functions as an intracellular checkpoint regulating activation of T cells, B-cells and NK cells.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Nurix Therapeutics Inc stock information, including NASDAQ:NRIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRIX stock methods without spending real money on the virtual paper trading platform.